The GPATCH3 Knockout NCI-H1975 Polyclonal Cells encompass a CRISPR/Cas9-edited polyclonal knockout cell population targeting the GPATCH3 gene in the human NCI-H1975 non-small cell lung adenocarcinoma line. This polyclonal pool constitutes a heterogeneous loss-of-function model that circumvents the artifacts of clonal selection, thereby offering a more representative system for functional genomics. The knockout was introduced via CRISPR/Cas9-mediated gene disruption, resulting in a diversified mutation spectrum at the GPATCH3 locus across the population, which is well-suited for robust, population-level analyses in vitro.
NCI-H1975 is a well-characterized human lung adenocarcinoma cell line harboring the clinically relevant EGFR T790M and L858R mutations. The T790M gatekeeper mutation enhances affinity for ATP and reduces binding of first-generation EGFR tyrosine kinase inhibitors, while L858R constitutively activates the kinase domain. This unique combination drives oncogenic signaling and is a central model for studying acquired resistance to EGFR-targeted therapies in non-small cell lung cancer (NSCLC). Due to these features, NCI-H1975 is extensively employed to dissect EGFR downstream pathways, including AKT and mTOR, and to evaluate therapeutic strategies.
GPATCH3 encodes a G-patch domain-containing protein proposed to function as a splicing factor. It is predicted to interact physically with RNA helicases and core spliceosomal components such as SF3B1 and U2AF1, modulating the processing of pre-mRNA transcripts. In the EGFR signaling network, GPATCH3 is regulated downstream of EGFR and the MYC transcription factor, positioning it at the intersection of mitogenic signaling and RNA metabolism. Its activity may influence alternative splicing of key pathway genes, including those encoding EGFR pathway modulators and apoptosis regulators, thereby shaping the cellular response to oncogenic stimuli. Perturbation of GPATCH3 can disrupt splicing-dependent expression of targets within the AKT/mTOR axis, potentially affecting cell proliferation and survival.
Disruption of GPATCH3 in the NCI-H1975 EGFR-mutant context is anticipated to compromise the integrity of RNA splicing networks that support oncogenic programs. Loss of GPATCH3-mediated splicing may alter the expression or isoform profiles of genes critical for drug resistance, such as apoptosis regulators and EMT factors. Consequently, this knockout model provides a unique tool to investigate how splicing dysregulation contributes to the maintenance of the malignant phenotype and resistance to EGFR inhibitors. The interplay between GPATCH3 and key pathways like EGFR/AKT/mTOR makes this system valuable for identifying synthetic lethal interactions and alternative therapeutic targets in NSCLC.
This polyclonal knockout population is suitable for RNA-seq and RT-qPCR to assess splicing alterations and gene expression changes, and for western blotting and co-immunoprecipitation to validate protein interactions. Drug sensitivity assays can evaluate responses to EGFR tyrosine kinase inhibitors, splicing-modulator compounds, or standard chemotherapy, while apoptosis and migration assays enable functional phenotyping. These applications facilitate the study of GPATCH3??s contribution to lung adenocarcinoma biology and drug resistance. For further details, please contact Ascent Research.
